North America Human Leukocyte Antigen (HLA) Testing Market

The North America human leukocyte antigen (HLA) testing market is expected to grow from US$ 324.49 million in 2022 to US$ 504.72 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028.

Human leukocyte antigens (HLAs) are specialized proteins present on all cell surfaces of the human body except red blood cells. HLA testing has significant application in organ transplantation, which can be recommended as a part of the treatment of kidney failure, chronic liver cirrhosis, and chronic heart disease, among other medical issues. The growing prevalence of chronic diseases and organ failure leads to high demand for organ transplant procedures, as well as HLA testing. Before transplantation, HLA testing is performed to check tissue compatibility between patients and donors to avoid graft rejection. In recent years, transplantation has become a successful practice area. Governments of various countries are taking initiatives to spread awareness about the need for organ donation and the benefits of organ transplantation in certain treatment procedures. For instance, the Organ Procurement and Transplantation Network (OPTN) has implemented a few strategies to improve the number of organ transplantation procedures in the US. These strategies focus on increasing the number of organ and tissue transplants among patients with end-stage organ disease, altering the current organ distribution, and modifying the organ transplantation waitlist by redistributing the existing organ soppy. Furthermore, the OPTN has used out-of-box strategies to improve organ transplantation. These innovative strategies include the optimized use of organs obtained from deceased patients [e.g., donation after cardiac death (DCD) or brain-dead donors], reducing discards of organs, promoting living donation, and improving the rate of potential organ donation authorization. Thus, the growing demand for organ transplantation leads to the requirement of a more substantial number of HLA testing kits and consumables, which drives the HLA testing market.

With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the north america human leukocyte antigen (HLA) testing market at a notable CAGR during the forecast period.

North America Human Leukocyte Antigen (HLA) Testing Market Revenue and Forecast to 2028 (US$ Million)

North America Human Leukocyte Antigen (HLA) Testing Strategic Insights

Strategic insights for the North America Human Leukocyte Antigen (HLA) Testing provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

North America Human Leukocyte Antigen (HLA) Testing Report Scope

North America Human Leukocyte Antigen (HLA) Testing Regional Insights

The geographic scope of the North America Human Leukocyte Antigen (HLA) Testing refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

North America Human Leukocyte Antigen (HLA) Testing Market Segmentation  

The North America human leukocyte antigen (HLA) testing market is segmented into product & services, technology, end user, and country. Based on product & services, the market is segmented into reagents & consumables, instruments, and software & services. In terms of technology, the North America human leukocyte antigen (HLA) testing market is divided into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment is sub segmented into PCR-based molecular assays, sequencing-based molecular assays, and others. Based on end user, the market is divided into independent reference laboratories, hospital and transplant centers, and others. Based on country, the North America human leukocyte antigen (HLA) testing market is segmented into the US, Mexico, and Canada.

North America Human Leukocyte Antigen (HLA) Testing Market — Companies Mentioned

THERMO FISHER SCIENTIFIC INC.; CareDx; QIAGEN; Illumina, Inc.; Bio-Rad Laboratories, Inc.; TBG Diagnostics Limited; F. HOFFMANN-LA ROCHE LTD.; Takara Bio Inc.; Luminex Corporation; Omixon Inc.; The Sequencing Center; HistoGenetics LLC; CD Genomics; Quintara Biosciences; and CREATIVE BIOLABS, INC. are among the major companies operating in the North America human leukocyte antigen (HLA) testing market.